VistaGen Therapeutics Q3 Earnings Beat Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy VTGN?
Source: seekingalpha
- Earnings Highlights: VistaGen Therapeutics reported a Q3 GAAP EPS of -$0.45, beating expectations by $0.04, indicating a slight improvement in financial performance despite ongoing losses.
- Revenue Growth: The company achieved revenue of $0.30 million in Q3, representing a 30.4% year-over-year increase and exceeding market expectations by $0.16 million, suggesting rising demand for its products and laying a foundation for future growth.
- Expense Increase: General and administrative expenses rose to $5.6 million, up from $4.0 million in the same quarter last year, primarily due to increased consulting and professional fees, which may impact the company's profitability.
- Cash Reserves: As of December 31, 2025, the company reported cash, cash equivalents, and marketable securities totaling $61.8 million, demonstrating stability in liquidity that supports future R&D and operational needs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VTGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VTGN
Wall Street analysts forecast VTGN stock price to rise
5 Analyst Rating
0 Buy
5 Hold
0 Sell
Hold
Current: 0.545
Low
0.90
Averages
0.97
High
1.00
Current: 0.545
Low
0.90
Averages
0.97
High
1.00
About VTGN
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. Its neuroscience product candidates include Fasedienol, Itruvone, PH15, PH80, and PH284. Fasedienol, its lead clinical-stage product candidate, is a synthetic neuroactive intranasal pherine in an ongoing U.S. registration-directed Phase III clinical development program for the acute treatment of anxiety in adults with SAD. Its neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Class Action Filed Against Vistagen Therapeutics for Securities Violations
- Class Action Initiation: Bronstein, Gewirtz & Grossman has filed a class action lawsuit against Vistagen Therapeutics, seeking damages for investors who purchased securities between April 1, 2024, and December 16, 2025, reflecting strong investor response to potential fraud allegations.
- False Statement Allegations: The complaint alleges that Vistagen made materially false and misleading statements throughout the class period, particularly regarding the development and prospects of its drug fasedienol, severely undermining investor confidence in the company's future.
- Legal Consequences for Investors: Investors have until March 16, 2026, to apply as lead plaintiffs to participate in potential recoveries, highlighting the importance of legal proceedings in protecting investor rights.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman is renowned for recovering hundreds of millions for investors, emphasizing its expertise in securities fraud class actions and its commitment to restoring investor capital and ensuring corporate accountability.
See More
Vistagen Therapeutics Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Vistagen Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between April 1, 2024, and December 16, 2025, with a deadline to contact the firm by March 16, 2026.
- False Statements Allegation: The complaint alleges that Vistagen made false and misleading statements to the market, creating a false impression of likely Phase 3 success for its fasedienol drug candidate by downplaying the risks of failure in clinical studies.
- Investor Losses: When the market learned the truth about Vistagen, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period, adversely affecting investor decisions.
- Legal Consultation Opportunity: The Schall Law Firm encourages affected shareholders to proactively reach out for free legal consultations to discuss their rights before the class action is certified, ensuring investors can effectively protect their interests.
See More
Vistagen Investors Warned of Class Action Lawsuit
- Class Action Notice: The Portnoy Law Firm advises Vistagen Therapeutics investors of a class action lawsuit for those who purchased securities between April 1, 2024, and December 16, 2025, with a deadline of March 16, 2026, to file a lead plaintiff motion to protect their legal rights.
- Allegations of Misconduct: The lawsuit alleges that Vistagen failed to disclose the inherent risks of failure in the PALISADE-3 clinical trial for fasedienol, misleading investors about the likelihood of success and impacting their investment decisions.
- Stock Price Collapse: Following the announcement on December 17, 2025, that the PALISADE-3 trial did not meet its primary endpoint, Vistagen's stock price plummeted over 80%, significantly harming investor interests and raising concerns about corporate governance.
- Legal Support Offered: The Portnoy Law Firm offers complimentary case evaluations to assist investors in recovering losses due to corporate wrongdoing, demonstrating a commitment to protecting investor rights and interests.
See More
Vistagen Class Action Notice for Investors
- Lawsuit Timeline: Rosen Law Firm reminds investors who purchased Vistagen Therapeutics (NASDAQ: VTGN) common stock between April 1, 2024, and December 16, 2025, that they must apply to be lead plaintiff by March 16, 2026, to protect their rights in the class action lawsuit.
- Fee Arrangement: Investors joining the Vistagen class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected investors to participate.
- Case Background: The lawsuit alleges that Vistagen provided overly optimistic projections regarding its drug fasedienol's clinical trial while concealing significant adverse facts related to the PALISADE-3 trial, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having achieved the largest settlement against a Chinese company and recovering hundreds of millions for investors, making it a preferred choice for investors seeking qualified legal counsel.
See More
Vistagen Faces Securities Litigation Investigation
- Litigation Investigation Launched: Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics, Inc., particularly for investors who purchased securities between April 1, 2024, and December 16, 2025, urging them to seek lead plaintiff status by the March 16, 2026 deadline.
- False Statement Allegations: The lawsuit alleges that Vistagen and its executives violated federal securities laws by making false and misleading statements regarding the success of fasedienol's clinical trials, leading investors to purchase stock at artificially inflated prices, resulting in significant financial losses.
- Stock Price Plummet: Following the December 17, 2025 announcement that the PALISADE-3 study failed to meet its primary efficacy endpoint, Vistagen's stock price fell over 81% to $0.88 per share at market open, severely impacting investor confidence.
- Investor Rights Protection: Faruqi & Faruqi encourages anyone with information regarding Vistagen's conduct, including whistleblowers and former employees, to come forward to provide legal support and share information for affected investors.
See More
Vistagen Therapeutics Accused of Misleading Investors
- Class Action Filed: Robbins LLP reminds investors that a class action has been initiated on behalf of those who purchased Vistagen Therapeutics (NASDAQ: VTGN) common stock between April 1, 2024, and December 16, 2025, indicating significant legal exposure for the company.
- Trial Results Disappoint: On December 17, 2025, Vistagen announced that its PALISADE-3 trial for Fasedienol did not achieve statistically significant improvement on the primary endpoint, leading to a dramatic stock price drop of over 80%.
- Stock Price Volatility: Following the trial announcement, Vistagen's stock plummeted from $4.36 per share on December 16, 2025, to $0.86 per share, reflecting a severe loss of investor confidence in the company's future prospects.
- Investor Action Guidance: Shareholders are advised to submit their papers by March 16, 2026, to serve as lead plaintiff in the class action, highlighting urgent issues regarding corporate governance and transparency that need to be addressed.
See More
Class Action Filed Against Vistagen Therapeutics for Securities Violations
- Class Action Initiation: Bronstein, Gewirtz & Grossman has filed a class action lawsuit against Vistagen Therapeutics, seeking damages for investors who purchased securities between April 1, 2024, and December 16, 2025, reflecting strong investor response to potential fraud allegations.
- False Statement Allegations: The complaint alleges that Vistagen made materially false and misleading statements throughout the class period, particularly regarding the development and prospects of its drug fasedienol, severely undermining investor confidence in the company's future.
- Legal Consequences for Investors: Investors have until March 16, 2026, to apply as lead plaintiffs to participate in potential recoveries, highlighting the importance of legal proceedings in protecting investor rights.
- Law Firm Credentials: Bronstein, Gewirtz & Grossman is renowned for recovering hundreds of millions for investors, emphasizing its expertise in securities fraud class actions and its commitment to restoring investor capital and ensuring corporate accountability.
See More
Vistagen Therapeutics Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Vistagen Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between April 1, 2024, and December 16, 2025, with a deadline to contact the firm by March 16, 2026.
- False Statements Allegation: The complaint alleges that Vistagen made false and misleading statements to the market, creating a false impression of likely Phase 3 success for its fasedienol drug candidate by downplaying the risks of failure in clinical studies.
- Investor Losses: When the market learned the truth about Vistagen, investors suffered damages, indicating that the company's public statements were false and materially misleading throughout the class period, adversely affecting investor decisions.
- Legal Consultation Opportunity: The Schall Law Firm encourages affected shareholders to proactively reach out for free legal consultations to discuss their rights before the class action is certified, ensuring investors can effectively protect their interests.
See More
Vistagen Investors Warned of Class Action Lawsuit
- Class Action Notice: The Portnoy Law Firm advises Vistagen Therapeutics investors of a class action lawsuit for those who purchased securities between April 1, 2024, and December 16, 2025, with a deadline of March 16, 2026, to file a lead plaintiff motion to protect their legal rights.
- Allegations of Misconduct: The lawsuit alleges that Vistagen failed to disclose the inherent risks of failure in the PALISADE-3 clinical trial for fasedienol, misleading investors about the likelihood of success and impacting their investment decisions.
- Stock Price Collapse: Following the announcement on December 17, 2025, that the PALISADE-3 trial did not meet its primary endpoint, Vistagen's stock price plummeted over 80%, significantly harming investor interests and raising concerns about corporate governance.
- Legal Support Offered: The Portnoy Law Firm offers complimentary case evaluations to assist investors in recovering losses due to corporate wrongdoing, demonstrating a commitment to protecting investor rights and interests.
See More
Vistagen Class Action Notice for Investors
- Lawsuit Timeline: Rosen Law Firm reminds investors who purchased Vistagen Therapeutics (NASDAQ: VTGN) common stock between April 1, 2024, and December 16, 2025, that they must apply to be lead plaintiff by March 16, 2026, to protect their rights in the class action lawsuit.
- Fee Arrangement: Investors joining the Vistagen class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected investors to participate.
- Case Background: The lawsuit alleges that Vistagen provided overly optimistic projections regarding its drug fasedienol's clinical trial while concealing significant adverse facts related to the PALISADE-3 trial, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having achieved the largest settlement against a Chinese company and recovering hundreds of millions for investors, making it a preferred choice for investors seeking qualified legal counsel.
See More
Vistagen Faces Securities Litigation Investigation
- Litigation Investigation Launched: Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics, Inc., particularly for investors who purchased securities between April 1, 2024, and December 16, 2025, urging them to seek lead plaintiff status by the March 16, 2026 deadline.
- False Statement Allegations: The lawsuit alleges that Vistagen and its executives violated federal securities laws by making false and misleading statements regarding the success of fasedienol's clinical trials, leading investors to purchase stock at artificially inflated prices, resulting in significant financial losses.
- Stock Price Plummet: Following the December 17, 2025 announcement that the PALISADE-3 study failed to meet its primary efficacy endpoint, Vistagen's stock price fell over 81% to $0.88 per share at market open, severely impacting investor confidence.
- Investor Rights Protection: Faruqi & Faruqi encourages anyone with information regarding Vistagen's conduct, including whistleblowers and former employees, to come forward to provide legal support and share information for affected investors.
See More
Vistagen Therapeutics Accused of Misleading Investors
- Class Action Filed: Robbins LLP reminds investors that a class action has been initiated on behalf of those who purchased Vistagen Therapeutics (NASDAQ: VTGN) common stock between April 1, 2024, and December 16, 2025, indicating significant legal exposure for the company.
- Trial Results Disappoint: On December 17, 2025, Vistagen announced that its PALISADE-3 trial for Fasedienol did not achieve statistically significant improvement on the primary endpoint, leading to a dramatic stock price drop of over 80%.
- Stock Price Volatility: Following the trial announcement, Vistagen's stock plummeted from $4.36 per share on December 16, 2025, to $0.86 per share, reflecting a severe loss of investor confidence in the company's future prospects.
- Investor Action Guidance: Shareholders are advised to submit their papers by March 16, 2026, to serve as lead plaintiff in the class action, highlighting urgent issues regarding corporate governance and transparency that need to be addressed.
See More
